| Current Price | $56.42 | Mkt Cap | $5.7B |
|---|---|---|---|
| Open | $57.69 | P/E Ratio | 77.90 |
| Prev. Close | $56.42 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $56.11 - $57.69 | Volume | 1,531,453 |
| 52-Wk Range | $54.19 - $64.00 | Avg. Daily Vol. | 2,719,373 |
A development stage nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy.
| Current Price | $56.42 | Mkt Cap | $5.7B |
|---|---|---|---|
| Open | $57.69 | P/E Ratio | 77.90 |
| Prev. Close | $56.42 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $56.11 - $57.69 | Volume | 1,531,453 |
| 52-Wk Range | $54.19 - $64.00 | Avg. Daily Vol. | 2,719,373 |
The best Bull and Bear pitches based on recency and number of recommendations.
Arrowhead Pharmaceuticals stock rockets 30% after upbeat trial data prompts analyst upgrade,MarketWatch•September 6, 2018MARKET PULSE Shares of Arrowhead Pharmaceuticals Corp. (arwr) rocketed 30% toward a 4 1/2-year high in premarket trade Thursday,… More
Short-term CAPS pick, would like to green thumb at a much lower market cap...From 12/04/2019: "Arrowhead Pharmaceuticals ended September with more than $258 million in cash and short-term investments. The recent public stock offering will nearly… More
Read the most recent pitches from players about ARWR.
Recs
TMFBlacknGold
(96.65)
Submitted: 12/13/2019 10:25:32 AM :
Start Price:
$70.74
NASDAQ:ARWR Score:
+27.86
Short-term CAPS pick, would like to green thumb at a much lower market cap...
From 12/04/2019:
"Arrowhead Pharmaceuticals ended September with more than $258 million in cash and short-term investments. The recent public stock offering will nearly double the company's financial flexibility. That should be comforting to investors, as it de-risks drug development from a pipeline buzzing with activity, but a market cap of $6 billion is certainly generous for the RNAi developer -- barring an acquisition, of course."
https://www.fool.com/investing/2019/12/04/heres-why-arrowhead-pharmaceuticals-is-tumbling-to.aspx
Recs
Bigsef77
(68.94)
Submitted: 9/6/2018 11:23:29 AM :
Start Price:
$1.52
NASDAQ:ARWR Score:
+3,572.84
Arrowhead Pharmaceuticals stock rockets 30% after upbeat trial data prompts analyst upgrade
,MarketWatch•September 6, 2018
MARKET PULSE Shares of Arrowhead Pharmaceuticals Corp. (arwr) rocketed 30% toward a 4 1/2-year high in premarket trade Thursday, after upbeat results of the company's treatment for chronic hepatitis B prompted an upgrade at B.
Recs
Quickcard
(< 20)
Submitted: 10/10/2017 5:07:56 PM :
Start Price:
$4.02
NASDAQ:ARWR Score:
+1,273.02
Pharma companies with what are doing research with verifiable positive results in treatment for especially intractable medical conditions seem to be on a roll. I don't see this should not continue, especially as DNA/RNA research is reaching new highs at the same time.
Find the members with the highest scoring picks in ARWR.
mistermiranga (99.75) Score: +3,762.61
ZZ Langerhans has left the building. trying to grab his own bottom now. I am king!
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
|
mistermiranga | 99.75 | 12/1/2016 |
|
5Y | $1.41 | +3,915.66% | +50.87% | +3,864.79 | 0 Comment |
| Bigsef77 | 68.94 |
|
|
3Y | $1.52 | +3,612.09% | +39.24% | +3,572.84 | 1 Comment | |
| KidJones | 34.01 | 4/22/2013 |
|
5Y | $1.78 | +3,069.66% | +113.15% | +2,956.51 | 0 Comment | |
| whoodatstockhot | 85.12 | 7/8/2013 |
|
5Y | $2.02 | +2,693.07% | +102.64% | +2,590.43 | 0 Comment | |
| EvilEmpire | 30.45 | 2/28/2013 |
|
5Y | $2.20 | +2,464.55% | +118.60% | +2,345.95 | 0 Comment | |
| MFBurritoSquat | 92.43 | 12/19/2012 |
|
3M | $2.23 | +2,430.04% | +128.17% | +2,301.88 | 0 Comment | |
| hayrettin | 70.97 | 8/24/2017 |
|
5Y | $2.50 | +2,161.32% | +35.79% | +2,125.54 | 0 Comment | |
| AJL7 | < 20 | 2/3/2016 |
|
5Y | $3.26 | +1,630.67% | +73.48% | +1,557.20 | 0 Comment | |
| beecha | < 20 | 9/19/2017 |
|
5Y | $3.35 | +1,584.18% | +32.82% | +1,551.36 | 0 Comment | |
|
|
Under5 | < 20 | 9/13/2017 |
|
5Y | $3.42 | +1,552.12% | +32.84% | +1,519.29 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
